Don't Miss our Black Friday Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Iterum Therapeutics (ITRM) has shared an update.
Iterum Therapeutics International Limited has contracted its outgoing Chief Medical Officer, Dr. Sailaja Puttagunta, as a consultant during the regulatory review of its new drug application for a urinary tract infection treatment. Dr. Puttagunta will be compensated at $400 per hour. Concurrently, the company is striving to regain compliance with Nasdaq Listing Rule 5550(b)(1) after being notified of a deficit in stockholders’ equity, with a deadline of September 30, 2024, to avoid delisting. Additionally, the FDA has acknowledged the resubmission of the company’s new drug application and set a review deadline for October 25, 2024.
For detailed information about ITRM stock, go to TipRanks’ Stock Analysis page.
